Flynn James P — SEC insider filings
SEC reporting owner CIK 1955965. 15 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2022-12-19 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 4 filings — 134,550 shares, $163,412 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: purchase of 70,000 shares @ $1.40 ($97,699) in Lite Strategy, Inc., filed 2025-12-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lite Strategy, Inc. (LITS) | Director | 11 | 4 legs · 134,550 sh · $163,412 | — | 9 |
| ARCA biopharma, Inc. (ABIO) | Director | 2 | — | — | 2 |
| SYNLOGIC, INC. (SYBX) | Director | 2 | — | — | 2 |
Insider filings — Flynn James P
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Lite Strategy, Inc. (LITS) | Purchase (P): 27,450 @ $0.79 | EDGAR |
| 2026-10-26 | 4 | Lite Strategy, Inc. (LITS) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Lite Strategy, Inc. (LITS) | Purchase (P): 25,000 @ $0.86 | EDGAR |
| 2025-12-22 | 4 | Lite Strategy, Inc. (LITS) | Purchase (P): 70,000 @ $1.40 | EDGAR |
| 2025-11-20 | 4 | Lite Strategy, Inc. (LITS) | Purchase (P): 12,100 @ $1.88 | EDGAR |
| 2025-11-18 | 4 | Lite Strategy, Inc. (LITS) | Grant/award (A): 55,000 (derivative) | EDGAR |
| 2025-10-02 | 4 | Lite Strategy, Inc. (LITS) | Grant/award (A): 10,000 @ $2.54 | EDGAR |
| 2025-07-17 | 4 | MEI Pharma, Inc. (MEIP) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | SYNLOGIC, INC. (SYBX) | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2024-05-20 | 4 | MEI Pharma, Inc. (MEIP) | Grant/award (A): 7,900 @ $3.16 | EDGAR |
| 2024-03-21 | 4 | SYNLOGIC, INC. (SYBX) | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | ARCA biopharma, Inc. (ABIO) | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-12 | 4/A | MEI Pharma, Inc. (MEIP) | Grant/award (A): 6,700 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-12-20 | 4 | MEI Pharma, Inc. (MEIP) | Grant/award (A): 6,700 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | ARCA biopharma, Inc. (ABIO) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1955965 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs